Palvella Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-12-31 was $0.00.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-09-30 was $0.00.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2021-06-30 was $837.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2019-12-31 was $141.00K, a 14000.00% increase year-over-year.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $70.60M.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $837.00K.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Palvella Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $246.00K, a 21.66% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-12-31 | $70.60M 10-K · filed 2026-03-31 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $837.00K 10-K · filed 2022-03-02 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | |
| 2021-06-30 | $837.00K 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $0.00 10-K · filed 2022-03-02 | |
| 2019-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $246.00K 10-K · filed 2021-03-31 |
| 2019-09-30 | $100.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $5.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $314.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $132.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $55.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $126.00K 10-Q · filed 2019-05-10 | |
| 2017-12-31 | $3.31M 10-K · filed 2019-03-18 | |
| 2014-12-31 | $4.38M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |